Mark Docherty, BEng ACA, Director of Finvector Vision Therapies Limited. He was a founding director of specialist life sciences venture capital company, Merlin Biosciences Limited (now Excalibur Fund Managers Limited) and was actively involved in the structuring and financing of the Merlin start-ups and investments. Previously, he was a Manager in the Corporate Finance Group of Arthur Andersen. He is a chartered accountant and holds a BEng in Mechanical Engineering from Sheffield University. He is a Geschäftsführer of DHP Private Equity GmbH, a specialist private equity house. He is also a non-executive director of ReNeuron Group plc.
Timo Ristola, Managing Director FinVector Oy, MSc (Economics), joined FinVector in January 2003 and has been responsible for FinVector Oy's planning , legal and commercial activities in Kuopio, Finland. Timo has about 20 years' experience in international groups within high-tech manufacturing operations in Finland on senior Treasury, Business Analyst, Finance, Controlling and General Management positions. His employees have been companies such as Asset Management Company Arsenal (FI), Fujitsu (ICL) Siemens Computers (GER/UK), Nokia Mobile Phones (FI), Assa Abloy (SWE) and Ark Therapeutics (FI) in chronological order.
Robert Shaw, Chief Operating Officer and Qualified Person joined in June 2005, having previously acted as a consultant to the Company on operational matters. Robert oversees FinVector’s manufacturing operational activities and manufacturing development within FinVector.
Robert is also responsible for FinVectors quality management - as Responsible Director in Kuopio, Finland. He is an industrial pharmacist with a record of achievements, both in the industrialisation of new processes and the management of established products.
Kassim Kolia, Head of Business Development, joined in 2012 and is responsible for Business Development, Sales and Marketing and Gene Therapy Market Intelligence within FinVector. He has over 15 years in product development and cGMP manufacturing. Kassim joined FinVector from Eden Biodesign Limited, part of Watson Pharmaceuticals, Inc., (now Actavis) where, since 2006, he has been responsible for the business development of Eden Biodesign's contract development and manufacturing services and under Watson responsible for Business Development activities on Biosimilar’s and Biologic technologies. Before joining Eden Biodesign, Kassim was Key Account Manager at Bachem (UK) Ltd where he was responsible for business development of cGMP business opportunities for the company in the UK and Ireland. Prior to that, Kassim has extensive hands on cGMP manufacturing experience having held roles of cGMP Line Manager at Lonza Biologics and Team Leader at Evotec.
Minna Karhinen, PhD, Manufacturing and Development Director at Finvector Vision Therapies Oy. Minna joined Finvector in 2003 and she leads Finvector's manufacturing and development for gene theraphy and other biological products. She has proven experience in the research, development and manufacturing of novel technologies. Extensive experience in doing biological research and development using techniques of molecular and cellular biology and recombinant DNA technology. Over 20 years experience in both basic and applied research in academia and in biotech company.
Minna Hassinen, Analytical Director at Finvector Vision Therapies Oy, Licentiate of Philosophy, (Biochemistry, Molecular Genetics). Joined company in April 2013. Is responsible for Analytical operations including Analytical Development and Quality Control. Has worked in the biotechnological industry for 10 years on Scientist, Quality Manager, Project Manager and Senior Manufacturing and Quality Control Executive positions. Operational experience includes; Analytical development, Quality control, Phase 2 clinical trial set up, Manufacturing and General Management operations. Her employees have been Nanobac Oy, Clinical research unit at University of Kuopio, Ark Therapeutics Oy, FKD Therapies Oy and Finvector Vision Therapies Oy.
Outi Närvänen works currently as Quality Director in Finvector Vision Therapies Oy. She is responsible for Quality Assurance operations and the overall management and maintenance of the cGMP compliant quality system. She has over 15 years experience in biotech pharma industry and before that nine years experience in diagnostic industry. Outi has graduated as MSc (cell biologist) in University of Jyväskylä in Finland. She worked since 1989 as scientist in diagnostic industry (Labsystems Oy, currently part of Thermo Fisher Scientific) first in R&D developing immunoassays for detection of infective viral diseases, later in manufacturing producing monoclonal antibodies against viral antigens in pilot scale bioreactor. She joined Finvector in 1998 and started with assay development. Since 2001 she has worked as QA manager/later director being responsible for QA operations and from 2013 as Quality Director. In Finvector Outi has gained experience in understanding the quality and regulatory requirements for gene-therapy and other biological products through development starting from preclinical product up to collecting CMC data package for a marketing approval.
Hanna P. Lesch, Research and Development Director, PhD (Molecular Medicine), started as graduate student in Finvector at 2001 and since then she has been working as research scientist, senior research scientist, and research assistant manager before the current role. Overall, Hanna has widely experienced in viral vectors based gene therapy and her special interest is in the field of process development. In addition, she has been working as biosafety officer. Her previous other positions has been as a post doc researcher at University of California San Diego and University of Eastern Finland.
FinVector is a world leader in the research and development of Viral-Based Gene Therapy products, with state-of-the-art facilities and a highly experienced scientific team working in the gene therapy market. We deliver a tailored service to meet and exceed our clients’ needs, and use our scientific expertise and industry knowledge to help clients take viral-based products from the pre-clinical phase, through clinical trials and to the market.
© FinVector Vision Therapies, 2014.